Ozempic, a diabetes medication widely used for weight loss, has driven over 60% growth in worldwide sales and led Novo Nordisk to more than double its net profit.
Novo Nordisk's dominance in Denmark, creating nearly half of all new private-sector nonfarm jobs and preventing the country's GDP from shrinking, raises concerns about reliance on a single company.
Collection
[
|
...
]